Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Cochlear's cash receipts from operating activities for the
six
months ended in Jun. 2026 was €746 Mil.
2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.
Cochlear's cash payments for the
six
months ended in Jun. 2026 was €-570 Mil.
3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.
Cochlear's cash payments for the
six
months ended in Jun. 2026 was €0 Mil.
4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.
Cochlear's cash payments for the
six
months ended in Jun. 2026 was €0 Mil.
5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.
Cochlear's cash payments for the
six
months ended in Jun. 2026 was €-4 Mil.
6. Interest Received:
It represents interest received by the company in the direct cash flow method.
Cochlear's cash payments for the
six
months ended in Jun. 2026 was €1 Mil.
7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.
Cochlear's cash payments for the
six
months ended in Jun. 2026 was €-32 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).
Cochlear's cash flow from others for the
six
months ended in Jun. 2026 was €-0 Mil.
Cochlear Cash Flow from Operations Related Terms
Cochlear Cash Flow from Operations Historical Data
* Premium members only.
The historical data trend for Cochlear's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Cochlear's Cash Flow from Operations for the fiscal year that ended in Jun. 2026 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €219 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Operations of €219 Mil mean?
Cochlear (FRA:OC5) has a Cash Flow from Operations of €219 Mil as of Jun. 2026. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Cochlear and its competitors.
Is Cochlear's Cash Flow from Operations too high?
Cochlear's current Cash Flow from Operations is €219 Mil. Overall, Cochlear has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Cash Flow from Operations compare to ABT and SYK?
Cochlear's Cash Flow from Operations of €219 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Medical Devices & Instruments company?
A good Cash Flow from Operations depends on the Medical Devices & Instruments industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Cochlear and its competitors. Cochlear's current Cash Flow from Operations is €219 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (FRA:OC5) is currently considered Significantly Undervalued. The stock's GF Value™ is €187.47, compared to a current price of €84.22 — trading 55.1% below its estimated fair value. The current Cash Flow from Operations is €219 Mil. Cochlear's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Cochlear (FRA:OC5), the current Cash Flow from Operations is €219 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cochlear (FRA:OC5) Overvalued in 2026?
Based on GuruFocus' analysis, Cochlear stock appears to be undervalued.
The current stock price of €84.22 is trading 55.1% below its estimated GF Value™ of €187.47.
GuruFocus considers Cochlear to be Significantly Undervalued.
Key valuation signals for FRA:OC5:
Cash Flow from Operations: €219 Mil
GF Value™: €187.47 vs. price of €84.22 (55.1% below fair value)
No single metric tells the full story. See the FRA:OC5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
68GF Score
Get the complete analysis for FRA:OC5
Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OC5 has been successfully added to your 
